DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD).

伊利诺伊州迪尔菲尔德（商业新闻短讯）--巴克斯特国际公司（纽约证券交易所代码：BAX）是肾脏护理和重要器官支持领域的全球创新者，今天宣布的新数据显示，与高通量血液透析（HF HD）相比，由Theranova透析器启用的扩大血液透析（称为HDx疗法）在长达四年的时间内可降低约25%的全因死亡风险。

The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26..

这项研究“哥伦比亚扩大血液透析和高通量血液透析患者的生存：队列研究”于5月23日至26日在欧洲肾脏协会欧洲透析和移植协会（ERA-EDTA）大会第61届大会上发表。。

The new data is from a 48-month observational cohort study involving 1,092 dialysis patients at 11 Baxter Renal Care Services Centers in Colombia. In the study, 533 patients received high-flux hemodialysis and were compared to 559 patients who received HDx therapy. HDx therapy targets the efficient removal of large-middle molecules,1,2,3,4 allowing for filtration closer to that of the natural kidney.5,6 Many of these large-middle molecule uremic toxins have been linked to the development of inflammation, cardiovascular disease, and other comorbidities in dialysis patients.1,2,3,7 HDx therapy uses Baxter’s Theranova dialyzer equipped with the MCO membrane, which filters a wider range of middle molecule uremic toxins from the blood, specifically targeting the large-middle molecules not effectively removed by conventional hemodialysis therapies..

新数据来自一项为期48个月的观察性队列研究，涉及哥伦比亚11个巴克斯特肾脏护理服务中心的1092名透析患者。在该研究中，533名患者接受了高通量血液透析，并与559名接受HDx治疗的患者进行了比较。HDx疗法的目标是有效去除大分子，1,2,3,4，使过滤更接近天然肾脏。5,6许多这些大分子尿毒症毒素与炎症，心血管疾病和透析患者的其他合并症有关。1,2,3,7 HDx疗法使用配备MCO膜的Baxter Theranova透析器，该透析器可从血液中过滤更广泛的中分子尿毒症毒素，特别针对常规血液透析疗法无法有效去除的大分子。。

“It is very exciting to see the results of this four-year study, indicating approximately 25% lower mortality for chronic kidney patients with the use of Baxter’s Theranova dialyzer. Dialysis treatments that more closely mimic the natural kidney have been associated with lower comorbidities, offering a protective effect for kidney patients,” said Professor Peter Rutherford, MB BS, PhD, vice president, Medical Affairs, Kidney Care, Baxter..

“看到这项为期四年的研究结果非常令人兴奋，表明使用Baxter的Theranova透析器可使慢性肾脏病患者的死亡率降低约25%。更接近天然肾脏的透析治疗与较低的合并症相关，为肾脏病患者提供了保护作用，”Baxter肾脏护理医学事务副总裁Peter Rutherford教授说。。

In addition to its clearance profile, HDx therapy enabled by Theranova dialyzer is as simple to perform as conventional hemodialysis (HD) and was designed to work with all HD machines. This allows clinics to offer HDx therapy using existing resources and eliminates the need for special equipment and added clinic workflow, which is required for HDF.

除了清除率外，Theranova透析器启用的HDx治疗与常规血液透析（HD）一样简单，并且设计用于所有HD机器。这使得诊所可以使用现有资源提供HDx治疗，并且不需要特殊设备和增加HDF所需的诊所工作流程。

More than 14 million dialysis treatments have been performed worldwide using Theranova dialyzer in more than 850 clinics. More information on Baxter’s HDx therapy can be found at hdxtheranova.com..

在全球850多家诊所使用Theranova透析器进行了1400多万次透析治疗。有关巴克斯特HDx疗法的更多信息，请访问hdxtheranova.com。。

ERA-EDTA 2024 presentations can be viewed on the congress website. To access the specific abstract, visit NDT_39_13.pdf and refer to citation ID: gfae069.1521.

ERA-EDTA 2024演示文稿可在大会网站上查看。要访问特定摘要，请访问NDT\U 39\U 13.pdf并参考引文ID:gfae069.1521。

About THERANOVA Dialyzer

关于THERANOVA透析器

Theranova dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased effective removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome.

Theranova透析器适用于规定间歇性血液透析的慢性肾衰竭患者。它提供了扩大的溶质去除曲线，增加了各种中间分子（高达45 kDa）的有效去除，这些分子可能在尿毒症临床综合征中起病理作用。

Theranova dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for Theranova dialyzer and the set should represent less than 10% of the patient's blood volume..

Theranova透析器不适用于血液滤过或血液透析滤过治疗。Theranova透析器和透析器组的总体外血容量应小于患者血容量的10%。。

For single use only.

仅供一次性使用。

About Baxter

关于巴克斯特

Every day, millions of patients, caregivers, and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen.

每天，数以百万计的患者、护理人员和医疗保健提供者依赖巴克斯特领先的诊断、重症监护、肾脏护理、营养、医院和外科产品组合，这些产品用于患者之家、医院、医生办公室和其他护理场所。90多年来，我们一直在关键的十字路口运营，在那里，拯救和维持生命的创新与实现这一目标的医疗保健提供者相遇。

With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X/Twitter, LinkedIn and Facebook..

百特在全球100多个国家提供产品、数字健康解决方案和疗法，百特的全球员工现在正以公司丰富的医学突破传统为基础，推动下一代变革性医疗创新。要了解更多信息，请访问www.baxter.com，并在X/Twitter、LinkedIn和Facebook上关注我们。。

Rx only. For the safe and proper use of this device, refer to the Instructions for Use.

仅接收。为了安全正确地使用本设备，请参阅使用说明。

This release includes forward-looking statements concerning HDx therapy and Baxter’s Theranova dialyzer equipped with the MCO membrane, including their potential impact on patients and anticipated benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website.

本版本包括有关HDx治疗和配备MCO膜的Baxter Theranova透析器的前瞻性声明，包括它们对患者的潜在影响以及与其使用相关的预期益处。这些声明基于对许多重要因素的假设，包括以下因素，这些因素可能导致实际结果与前瞻性声明中的结果存在重大差异：满足监管和其他要求；监管机构和其他政府机构的行动；产品质量、制造或供应或患者安全问题；法律法规变更；以及巴克斯特最近在10-K表上提交的文件和其他SEC文件中确定的其他风险，所有这些都可以在巴克斯特的网站上找到。

Baxter does not undertake to update its forward-looking statements..

巴克斯特不承诺更新其前瞻性声明。。

Baxter, HDx, MCO and Theranova are trademarks of Baxter International Inc. or its subsidiaries.

Baxter、HDx、MCO和Theranova是Baxter International Inc.或其子公司的商标。

Hutchison CA, et al. The Rationale for Expanded Hemodialysis Therapy (HDx). Contrib Nephrol. 2017; 191:142-52.

Hutchison CA等人。扩大血液透析疗法（HDx）的基本原理。Contrib Nephrol公司。2017年；191:142-52。

Neirynck N, et al. An update on uremic toxins. Int Urol Nephrol. 2013; 45:139-50.

Neirynck N等人。尿毒症毒素的最新进展。Inturol Nephrol。2013年；45:139-50。

Duranton F, et al. European Uremic Toxin Work Group. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul; 23(7):1258-70.

Duranton F等人。欧洲尿毒症毒素工作组。尿毒症毒素的正常和病理浓度。J Am Soc Nephrol。2012年7月；23（7）：1258-1250年。

Rosner M, et al. Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol. 2021;16(12):1918-1928.

Rosner M等人。尿毒症毒素的分类及其在肾衰竭中的作用。临床J Am Soc Nephrol。2021年；16（12）：1918-1928年。

Zweigart C, et al. Medium cut-off membranes – closer to the natural kidney removal function. Int J Artif Organs. 2017; 40(7):328-334.

Zweigart C等人。中等截留膜-更接近天然肾脏去除功能。Int J人工器官。2017年；40（7）：328-334。

Boschetti-de-Fierro A, et al. MCO membranes: Enhanced Selectivity in High-Flux Class. Scientific Reports 2015; 5:18448.

Boschetti de Fierro A等人。MCO膜：高通量级选择性增强。2015年科学报告；5： 18448年。

Ronco C, et al. The rise of Expanded Hemodialysis. Blood Purif. 2017; 44:I–VIII.. Doi: 10.1159/000476012.

Ronco C等人，《扩大血液透析的兴起》。血液净化2017；44:I–VIII。。Doi:10.1159/000476012。